跳转至内容
Merck
CN

05-765

Anti-MLL/HRX Antibody, CT., clone 9-12

clone 9-12, Upstate®, from mouse

别名:

Histone-lysine N-methyltransferase 2A, Lysine N-methyltransferase 2A, ALL-1, CXXC-type zinc finger protein 7, Myeloid/lymphoid or mixed-lineage leukemia, Myeloid/lymphoid or mixed-lineage leukemia protein 1, Trithorax-like protein, Zinc finger protein HR

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Anti-MLL/HRX Antibody, CT., clone 9-12, clone 9-12, Upstate®, from mouse

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

9-12, monoclonal

species reactivity

mouse, human

manufacturer/tradename

Upstate®

technique(s)

ChIP: suitable
immunofluorescence: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... KMT2A(4297)

Analysis Note

Control
K562 nuclear extract
Evaluated by Western Blotting in K562 nuclear extract.
Western Blotting Analysis: 0.1-1 µg/mL of this antibody detected MLL C-terminal fragment (C180; MLLC) in K562 nuclear extract.

Application

Anti-MLL/HRX, C-term., clone 9-12 is a high quality mouse monoclonal antibody that has been validated and published for use in Chromatin Immunoprecipitation (ChIP), Immunofluorescence, Immunoprecipitation, and Western Blotting applications.
Immnuofluorescence Analysis: A representative lot detected MLL expression in SOX2+ cells in paraffin-embedded high-grade human gliomas sections (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the Hoxa10 and Meis promoters in mouse MLL-AF10 leukemia cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected an enhanced MLL occupancy at the Ink4a locus of 8-month-old than 2-month-old bEzTG mouse islets. The same age-dependent Ink4a locus enrichment was observed with H3K4me3, while the opposite trend was seen with Ezh and H3K27me3 enrichment at the same locus (Zhou, J.X., et al. (2013). J. Clin. Invest. 123(11):4849-4858).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the HOXA10 promoter region in G179NS and G411NS human glioblastoma neural stem cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the DNA replication origin (RD) as well as at both exon 1b and p16INK4a/p19ARF shared exon 2 in mouse embryonic fibroblast (MEF). An increased MLL enrichment at these sites was observed in senescent and Polycomb mutant MEFs (Agherbi, H., et al. (2009). PLoS One. 4(5):e5622).

Chromatin Immnuoprecipitation (ChIP) Analysis: A representative lot detected MLL occupancy at the Hoxa9 AB region using mouse embryonic fibroblast (MEF) chromatin preparation (Erfurth, F.E., et al. (2008). Proc. Natl. Acad. Sci. U.S.A. 105(21):7517-7522).

Immnuoprecipitation Analysis: A representative lot co-immunoprecipitated JmjD3 and RbBP5, but not Dnmt3a, with MLL from Min6 mouse insulinoma cell extract (Zhou, J.X., et al. (2013). J. Clin. Invest. 123(11):4849-4858).

Western Blotting Analysis: A representative lot detected higher MLL level in cultured glioblastoma neural stem (GNS) cells than neural stem (NS) cells, as well as MLL enrichment in the CD15+ fraction of freshly resected Glioblastoma (GBM) cells (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Western Blotting Analysis: A representative lot detected SET domain-containing C-terminal fragment of the MLL complex enzymatic subunit MLL (C180; MLLC) in anti-FLAG immunoprecipitate from HeLaS cells stably expressing FLAG-tagged hDPY-30 (Cho, Y.W., et al. (2007). J. Biol. Chem. 282(28):20395-20406).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Histones

Biochem/physiol Actions

This monoclonal antibody targets the C-terminal proteolytic fragment of MLL (C180; MLLC). A reduced target band detection by this antibody was seen lysate from G411NS human glioblastoma neural stem cells transfected with MLL shRNA (Gallo, M., et al. (2013). Cancer Res. 73(1):417-427).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The acute lymphoblastic leukaemia (ALL)-1 (also known as MLL, HRX, HTRX, and TRX1) gene on human chromosome 11q23 is the site of many locally clustered chromosomal alterations associated with several types of acute leukaemias, including deletions, partial duplications and translocations. Structurally variant proteins derived from the altered gene presumably cause the malignant transformation of early haemopoietic progenitor cells.
~180 kDa observed. 134.4 kDa (a.a. 2719-3969; human MLL cleavage product C180) and 431.8/427.7/432.1 kDa (human full-length MLL isoform 1/2 (14P-18B)/3) calculated.

Immunogen

Epitope: MLL C-terminal fragment
MBP-tagged recombinant human mixed lineage leukemia (MLL) protein C-terminal fragment (a.a. 3084-3959).

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Format: Purified
Protein G purified.
Purified mouse IgG1 in 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide before the addition of glycerol to 30%. Liquid at -20ºC

Preparation Note

Store for 2 years at -20ºC from date of shipment. For maximum recovery of product, centrifuge the vial prior to removing the cap.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 1


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression.
Erfurth, FE; Popovic, R; Grembecka, J; Cierpicki, T; Theisler, C; Xia, ZB; Stuart et al.
Proceedings of the National Academy of Sciences of the USA null
Laurie K Svoboda et al.
Oncotarget, 8(1), 458-471 (2016-11-27)
Developmental transcription programs are epigenetically regulated by the competing actions of polycomb and trithorax (TrxG) protein complexes, which repress and activate genes, respectively. Ewing sarcoma is a developmental tumor that is associated with widespread de-regulation of developmental transcription programs, including
Zhang Feng et al.
Frontiers in neuroanatomy, 14, 36-36 (2020-08-15)
Neuron apoptosis in ischemic penumbra was proved to be involved in ischemic stroke (IS) development and contributed to the poor prognosis of IS. Recent studies showed that aberrant trimethylation of histone H3 lysine 4 (H3K4me3) level was associated with cell
Tiziana Fioretti et al.
Cell biochemistry and function, 40(7), 706-717 (2022-08-19)
The chromosomal translocation t(4;11)(q21;q23), a hallmark of an aggressive form of acute lymphoblastic leukemia (ALL), encodes mixed-lineage leukemia (MLL)-AF4 oncogenic chimera that triggers aberrant transcription of genes involved in lymphocyte differentiation, including HOXA9 and MEIS1. The scaffold protein 14-3-3θ, which
Isabelle S Lucet et al.
The Journal of biological chemistry, 280(4), 2503-2511 (2004-11-16)
Members of the large serine resolvase family of site-specific recombinases are responsible for the movement of several mobile genetic elements; however, little is known regarding the structure or function of these proteins. TnpX is a serine recombinase that is responsible

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持